Treatment of high-expressing FGF19 or FGFR4 positive breast cancer cells with an antibody against FGF19 or siRNA to FGF19 sensitizes the cells to doxorubicin (Tiong et al., 2016). Here, FGF19 is linked to breast carcinoma.